Anecortave Acetate in Patients With Open-angle Glaucoma
Phase 2
Completed
- Conditions
- Open-angle Glaucoma
- Interventions
- Registration Number
- NCT00320203
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this study is to evaluate the safety, efficacy, and duration of effect of a single administration of Anecortave Acetate Depot for treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 86
Inclusion Criteria
- Patients 18 years of age or older with open-angle glaucoma.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- Patients with open-angle glaucoma with a pseudoexfoliation or pigment dispersion component.
- Other protocol-defined exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Anecortave Acetate 15 mg Depot Anecortave Acetate Sterile Suspension, 30 mg/mL Single injection, anterior juxtascleral depot (AJD) Anecortave Acetate 30 mg Depot Anecortave Acetate Sterile Suspension, 60 mg/mL Single injection, anterior juxtascleral depot (AJD) Anecortave Acetate 3 mg Depot Anecortave Acetate Sterile Suspension, 6 mg/mL Single injection, anterior juxtascleral depot (AJD) Anecortave Acetate Vehicle Anecortave Acetate Vehicle Single injection, anterior juxtascleral depot (AJD)
- Primary Outcome Measures
Name Time Method Mean change in intraocular pressure at 9 am from baseline Weeks 2 and 6, Months 2, 3, 4, 5, 6, 7.5, 9, 10.5, and 12
- Secondary Outcome Measures
Name Time Method Time to treatment failure At time point